Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

A Review on Comparison of Allopathic Medicines to other Drug Therapies in the Management of Asthma

Author(s): Ruchika Garg*, Mona Piplani, Ashutosh Upadhayay, Yogendra Singh and Pankaj Bhateja

Volume 24, Issue 2, 2024

Published on: 20 October, 2023

Article ID: e201023222496 Pages: 12

DOI: 10.2174/0118715265249796231018050521

Price: $65

conference banner
Abstract

Asthma, is a chronic disease of the airways and is characterized by exacerbations of bronchospasm and noticeable airway inflammation. Current asthma therapy has emerged from naturally occurring compounds through rational pharmaceutical advancements, and it is very beneficial. In this review, we have discussed the different drug therapies i.e., Ayurvedic, Homeopathic, Unani, and Allopathic affecting asthma treatment. Allopathic medicines are used as a controller medication for regular maintenance of asthma i.e., long-acting β-agonists, inhaled corticosteroids, anti-leukotriene medicines, and novel biologic agents. Pharmacological research is more important in generating effective, long-lasting, and safe asthma treatments, but it has been difficult to produce new classes of anti-asthmatic therapies. A combination inhaler that contains a long-acting β2-agonist and a corticosteroid is currently the "gold standard" for treating asthma. Allopathic treatments for asthma have been proven effective in reducing the probability of asthma attacks and for improving symptoms along with lung functions as compared to other therapies. The level of asthma management and the possible risk of future worsening are used to determine the treatment's strategies. This review article describes the comparison of allopathic therapy of asthma with homeopathy, ayurvedic and Unani system and gives justification supported by a number of case studies for being allopathic, a better therapy when compared with others.

Graphical Abstract

[1]
Panda A, Doddanagali SR. Clinical efficacy of herbal Padmapatradi yoga in bronchial asthma (Tamaka Swasa). J Ayurveda Integr Med 2011; 2(2): 85-90.
[http://dx.doi.org/10.4103/0975-9476.82522] [PMID: 21760694]
[2]
Behera D. Bronchial asthma. New Delhi: Jaypee Brothers 2000.
[3]
Bielory L, Lupoli K. Herbal interventions in asthma and allergy. J Asthma 1999; 36(1): 1-65.
[http://dx.doi.org/10.3109/02770909909065150] [PMID: 10077136]
[4]
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17(1): 1-12.
[http://dx.doi.org/10.1016/0197-2456(95)00134-4] [PMID: 8721797]
[5]
Huntley A, Ernst E. Herbal medicines for asthma: A systematic review. Thorax 2000; 55(11): 925-9.
[http://dx.doi.org/10.1136/thorax.55.11.925] [PMID: 11050261]
[6]
Boly R, Yabre Z, Nitiema M, et al. Pharmacological evaluation of the bronchorelaxant effect of waltheria indica L. (Malvaceae) extracts on rat trachea. Evid Based Complement Alternat Med 2021; 2021: 1-8.
[http://dx.doi.org/10.1155/2021/5535727] [PMID: 33995545]
[7]
Kasirajan B, Maruthamuthu R, Gopalakrishnan V, et al. A database for medicinal plants used in treatment of asthma. Bioinformation 2007; 2(3): 105-6.
[http://dx.doi.org/10.6026/97320630002105] [PMID: 18288333]
[8]
Kumar GL, Mahendra S, Richa S, Rajesh D. Pharmaceutico analytical study and comparative antimicrobial effect of hartalabhasma and hartalagodantibhasma. Int J Ayurveda Pharma Res 2013; 1(3): 36-46.
[9]
Singh BB, Khorsan R, Vinjamury SP, Der-Martirosian C, Kizhakkeveettil A, Anderson TM. Herbal treatments of asthma: A systematic review. J Asthma 2007; 44(9): 685-98.
[http://dx.doi.org/10.1080/02770900701247202] [PMID: 17994396]
[10]
Clarke R, Lundy FT, McGarvey L. Herbal treatment in asthma and COPD - current evidence. Clin Phytosci 2015; 1(1): 4.
[http://dx.doi.org/10.1186/s40816-015-0005-0]
[11]
Singh SK, Patel JR, Dubey PK, Thakur S. A review on antiasthmatic activity of traditional medicinal plants. Int J Pharm Sci Res 2014; 5(10): 4097.
[12]
Mahammad Y, Mahamad I. Anti histaminic herbal drugs: A review. Int J Pharm Pharm Sci 2010; 2: 28-9.
[13]
Srivastava KC. Extract of a spice - Omum (Trachyspermum ammi)-shows antiaggregatory effects and alters arachidonic acid metabolism in human platelets. Prostaglandins Leukot Essent Fatty Acids 1988; 33(1): 1-6.
[http://dx.doi.org/10.1016/0952-3278(88)90115-9] [PMID: 3141935]
[14]
Paudyal B, Thapa A, Sigdel KR, Adhikari S, Basnyat B. Adverse events with ayurvedic medicines-possible adulteration and some inherent toxicities. Wellcome Open Res 2019; 4: 23.
[http://dx.doi.org/10.12688/wellcomeopenres.15096.3]
[15]
Jude S. Ayurvedic and Traditional Systems of Medicine in Clinical Trials: An Overview. In: Chemistry, Biological Activities and Therapeutic Applications of Medicinal Plants in Ayurveda. 2022.
[16]
Shah J. Homeopathic remedies. Available from:https://www.practo.com/healthfeed/homeopathic-remedies-for-asthma-26893/post (cited: 18 October 2022)
[17]
Jain JP. A clinical trial of Kantakari in cases of tamakswasa (some respiratory diseases). J Res Ayur Siddha 1980; 1: 447-60.
[18]
Jaber R. Respiratory and allergic diseases: From upper respiratory tract infections to asthma. Prim Care 2002; 29(2): 231-61.
[http://dx.doi.org/10.1016/S0095-4543(01)00008-2] [PMID: 12391710]
[19]
Khuda-Bukhsh AR, Roy-Karmakar S, Banerjee A, et al. A follow-up study on the efficacy of the homeopathic remedy arsenicum album in volunteers living in high risk arsenic contaminated areas. Evid Based Complement Alternat Med 2011; 2011: 1-9.
[http://dx.doi.org/10.1093/ecam/nep122] [PMID: 19703926]
[20]
Arantes S, Candeias F, Lopes O, et al. Pharmacological and toxicological studies of essential oil of Lavandula stoechas subsp. luisieri. Planta Med 2016; 82(14): 1266-73.
[http://dx.doi.org/10.1055/s-0042-104418] [PMID: 27124241]
[21]
Arora P, Ansari SH, Najmi AK, Anjum V, Ahmad S. Investigation of anti-asthmatic potential of dried fruits of Vitis vinifera L. in animal model of bronchial asthma. Allergy Asthma Clin Immunol 2016; 12(1): 42.
[http://dx.doi.org/10.1186/s13223-016-0145-x] [PMID: 27536321]
[22]
Ahmed N, Zakir M, Alam MA, Javed G, Minhajuddin A. Management of asthma (ḌĪQ Al-Nafas) in unani system of medicine. Int J Health Sci 2022; 13036-54.
[23]
Passalacqua G, Bousquet PJ, Carlsen KH, et al. ARIA update: I-Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol 2006; 117(5): 1054-62.
[http://dx.doi.org/10.1016/j.jaci.2005.12.1308] [PMID: 16675332]
[24]
Garg R, Dobhal K, Saklani T, et al. Covid-19: A challenge towards the sustainability of health in platform era. J Pharm Negat Results 2022; 1666-78.
[25]
Dobhal K, Ghildiyal P, Ansori ANM, Jakhmola V. An international outburst of new form of monkeypox virus. J Pure Appl Microbiol 2022; 16 (Suppl. 1): 3013-24.
[http://dx.doi.org/10.22207/JPAM.16.SPL1.01]
[26]
Berezin AA. Isotopical positional correlations as a possible model for Benveniste experiments. Med Hypotheses 1990; 31(1): 43-5.
[http://dx.doi.org/10.1016/0306-9877(90)90053-H] [PMID: 2314323]
[27]
Dorsch W, Stuppner H, Wagner H, Gropp M, Demoulin S, Ring J. Antiasthmatic effects of Picrorhiza kurroa: Androsin prevents allergen- and PAF-induced bronchial obstruction in guinea pigs. Int Arch Allergy Immunol 1991; 95(2-3): 128-33.
[http://dx.doi.org/10.1159/000235416] [PMID: 1718906]
[28]
Boskabady MH, Mohsenpoor N, Takaloo L. Antiasthmatic effect of Nigella sativa in airways of asthmatic patients. Phytomedicine 2010; 17(10): 707-13.
[http://dx.doi.org/10.1016/j.phymed.2010.01.002] [PMID: 20149611]
[29]
Sagar R, Sahoo HB. Evaluation of antiasthmatic activity of ethanolic extract of Elephantopus scaber L. leaves. Indian J Pharmacol 2012; 44(3): 398-401.
[http://dx.doi.org/10.4103/0253-7613.96347] [PMID: 22701255]
[30]
McCarney RW, Linde K, Lasserson TJ. Homeopathy for chronic asthma. Cochrane Database Syst Rev 2004; 2004(1): CD000353.
[http://dx.doi.org/10.1002/14651858.CD000353.pub2]
[31]
Anagnostatos GS. Small water clusters (clathrates) in the preparation process of homoeopathy. In: Ultra high dilution: Physiology and physics. Dordrecht: Springer 1994.
[32]
Van Wassenhoven M. Scientific framework of homeopathy: Evidence-based homeopathy. Int J High Dilution Res 2008; 7(23): 72-92.
[33]
Ahmad W, Sofi G, Alam MA, Zulkifle M, Ahmad B. Understanding Holism in the light of principle underlying practice of Unani Medicine. Rev Environ Health 2022; 37(2): 189-99.
[http://dx.doi.org/10.1515/reveh-2021-0009] [PMID: 33984879]
[34]
Javed A. Asthma treatment in Unani medicines. Available from: https://www.unaniherbal.org/asthma-treatment-in-unani-medicines.html (cited: 25 November 2022)
[35]
Naaz F, Khan N. Medical tourism in India: Perspective of Unani medicine. J AYUSH:-Ayurveda, Yoga, Unani Siddha Homeop 2016; 5(3): 52-60.
[36]
Itrat M. Methods of health promotion and disease prevention in Unani medicine. J Educ Health Promot 2020; 9(1): 168.
[http://dx.doi.org/10.4103/jehp.jehp_618_19] [PMID: 33015201]
[37]
Asadi-Samani M, Bahmani M, Rafieian-Kopaei M. The chemical composition, botanical characteristic and biological activities of Borago officinalis: A review. Asian Pac J Trop Med 2014; 7: S22-8.
[http://dx.doi.org/10.1016/S1995-7645(14)60199-1] [PMID: 25312125]
[38]
Shamsi Y, Khan R, Nikhat S. Clinically significant improvement in a case of bronchial asthma with unani medicine: A case report. Trad Integr Med 2019; 4(3): 130-6.
[http://dx.doi.org/10.18502/tim.v4i3.1682]
[39]
Asthma symptoms, prevention and treatment. Available from: https://www.healthline.com/health/asthma#treatmentMelinda (cited: 8 December 2022).
[40]
Bronchodialators and corticosteroids. Available from:https://www.nhsinform.scot/tests-and-treatments/medicinesand-medical-aids/types-of-medicine/bronchodilators. (cited: 8 December 2022).
[41]
Matera MG, Page CP, Calzetta L, Rogliani P, Cazzola M. Pharmacology and therapeutics of bronchodilators revisited. Pharmacol Rev 2020; 72(1): 218-52.
[http://dx.doi.org/10.1124/pr.119.018150] [PMID: 31848208]
[42]
Asthma news. Long-Term control medications used to treat asthma. Available from: https://getasthmahelp.org/ltc-medications.aspx (cited: 8 December 2022)
[43]
Garg R, Piplani M, Singh Y, Joshi Y. Epidemiology, pathophysiology, and pharmacological status of asthma. Curr Respir Med Rev 2022; 18(4): 247-58.
[http://dx.doi.org/10.2174/1573398X18666220526164329]
[44]
Jayasinghe H, Kopsaftis Z, Carson K. Asthma bronchiale and exercise-induced bronchoconstriction. Respiration 2015; 89(6): 505-12.
[http://dx.doi.org/10.1159/000433559] [PMID: 26068579]
[45]
Domingo C, Rello J, Sogo A. As-needed ICS-LABA in mild asthma: What does the evidence say? Drugs 2019; 79(16): 1729-37.
[http://dx.doi.org/10.1007/s40265-019-01202-0] [PMID: 31584145]
[46]
Kim M. New asthma drug stops attacks. Available from:https://abc30.com/health-watch-asthma-new-drug-medicine/1085397/ (cited: 10 December 2022)
[47]
Papi A, Fabbri LM, Kerstjens HAM, Rogliani P, Watz H, Singh D. Inhaled long-acting muscarinic antagonists in asthma - A narrative review. Eur J Intern Med 2021; 85: 14-22.
[http://dx.doi.org/10.1016/j.ejim.2021.01.027] [PMID: 33563506]
[48]
Polosa R, Blackburn MR. Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease. Trends Pharmacol Sci 2009; 30(10): 528-35.
[http://dx.doi.org/10.1016/j.tips.2009.07.005] [PMID: 19762093]
[49]
Wanke T, Merkle M, Zifko U, et al. The effect of aminophylline on the force-length characteristics of the diaphragm. Am J Respir Crit Care Med 1994; 149(6): 1545-9.
[http://dx.doi.org/10.1164/ajrccm.149.6.8004311] [PMID: 8004311]
[50]
Vinotha ATS, Ranjani R. A prospective randomized controlled study: Theophylline on oxidative stress and steroid sensitivity in chronic obstructive pulmonary disease patients. Int J Pharm Investig 2017; 7(3): 119-24.
[http://dx.doi.org/10.4103/jphi.JPHI_58_17] [PMID: 29184823]
[51]
Mattikow MS. Aminophylline improves diaphragmatic contractility. N Engl J Med 1981; 305(22): 1349-50.
[http://dx.doi.org/10.1056/NEJM198111263052218] [PMID: 7290162]
[52]
Kim LHY, Saleh C, Whalen-Browne A, O’Byrne PM, Chu DK. Triple vs. dual inhaler therapy and asthma outcomes in moderate to severe asthma: A systematic review and meta-analysis. JAMA 2021; 325(24): 2466-79.
[http://dx.doi.org/10.1001/jama.2021.7872] [PMID: 34009257]
[53]
Weinberger M, Hendeles L. Theophylline in asthma. N Engl J Med 1996; 334(21): 1380-8.
[http://dx.doi.org/10.1056/NEJM199605233342107] [PMID: 8614425]
[54]
Sawicki G, Haver K, Wood RA, Redding G, TePas E. Asthma in children younger than 12 years: Initial evaluation and diagnosis. In: UpToDate. 2019.
[55]
Springer C, Goldenberg B, Dov I, Godfrey S. Clinical, physiologic, and psychologic comparison of treatment by cromolyn or theophylline in childhood asthma. J Allergy Clin Immunol 1985; 76(1): 64-9.
[http://dx.doi.org/10.1016/0091-6749(85)90806-1] [PMID: 3924984]
[56]
Drazen JM. Pharmacology of leukotriene receptor antagonists and 5‐lipoxygenase inhibitors in the management of asthma. Pharmacotherapy 1997; 17((1 Pt 2)): 22S-30S.
[57]
Zhang HP, Jia CE, Lv Y, Gibson PG, Wang G. Montelukast for prevention and treatment of asthma exacerbations in adults: Systematic review and meta-analysis. Allergy Asthma Proc 2014; 35(4): 278-87.
[58]
Rachelefsky G. Childhood asthma and allergic rhinitis: The role of leukotrienes. J Pediatr 1997; 131(3): 348-55.
[http://dx.doi.org/10.1016/S0022-3476(97)80057-1] [PMID: 9329408]
[59]
Leonardi A, Abelson MB. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin Ther 2003; 25(10): 2539-52.
[http://dx.doi.org/10.1016/S0149-2918(03)80315-6] [PMID: 14667955]
[60]
Côté A, Godbout K, Boulet LP. The management of severe asthma in 2020. Biochem Pharmacol 2020; 179: 114112.
[http://dx.doi.org/10.1016/j.bcp.2020.114112] [PMID: 32598948]
[61]
Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma. Allergy 2020; 75(5): 1023-42.
[http://dx.doi.org/10.1111/all.14221] [PMID: 32034960]
[62]
Ridolo E, Pucciarini F, Nizi MC, Makri E, Kihlgren P, Panella L. Mabs for treating asthma: Omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab. Hum Vaccin Immunother 2020; 16(10): 2349-56.
[http://dx.doi.org/10.1080/21645515.2020.1753440]
[63]
Mantoan GD. Childhood Asthma Control Intervention through Community Health Workers in the California Central Valley: A Mixed Methods Analysis of Feasibility, and Desirability of Addition of Peer Support. Merced: University of California 2022.
[64]
Qiu J, Grine K. Complementary and alternative treatment for allergic conditions. Prim Care 2016; 43(3): 519-26.
[http://dx.doi.org/10.1016/j.pop.2016.04.012] [PMID: 27545740]
[65]
Zainab R, Akram M, Daniyal M, Riaz M. Awareness and current therapeutics of asthma. Dose Response 2019; 17(3)
[http://dx.doi.org/10.1177/1559325819870900] [PMID: 31523203]
[66]
Komaromy M, Duhigg D, Metcalf A, et al. Project ECHO (Extension for Community Healthcare Outcomes): A new model for educating primary care providers about treatment of substance use disorders. Subst Abus 2016; 37(1): 20-4.
[http://dx.doi.org/10.1080/08897077.2015.1129388] [PMID: 26848803]
[67]
Tesse R, Borrelli G, Mongelli G, Mastrorilli V, Cardinale F. Treating pediatric asthma according guidelines. Front Pediatr 2018; 6: 234.
[http://dx.doi.org/10.3389/fped.2018.00234] [PMID: 30191146]
[68]
Lim TK. Corticosteroids in the emergency treatment of acute severe asthma. Chest 2000; 117(5): 1526-7.
[http://dx.doi.org/10.1378/chest.117.5.1526-a] [PMID: 10807855]
[69]
Bårnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: Current status and future perspectives. Respir Care 2015; 60(3): 455-68.
[http://dx.doi.org/10.4187/respcare.03200] [PMID: 25118311]
[70]
Chipps BE, Lanier B, Milgrom H, et al. Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience. J Allergy Clin Immunol 2017; 139(5): 1431-44.
[http://dx.doi.org/10.1016/j.jaci.2017.03.002] [PMID: 28477722]
[71]
Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009; 124(6): 1210-6.
[http://dx.doi.org/10.1016/j.jaci.2009.09.021] [PMID: 19910033]
[72]
Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43(2): 343-73.
[http://dx.doi.org/10.1183/09031936.00202013] [PMID: 24337046]
[73]
McKeever T, Mortimer K, Wilson A, et al. Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations. N Engl J Med 2018; 378(10): 902-10.
[http://dx.doi.org/10.1056/NEJMoa1714257] [PMID: 29504499]
[74]
Ducharme FM, Lemire C, Noya FJD, et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N Engl J Med 2009; 360(4): 339-53.
[http://dx.doi.org/10.1056/NEJMoa0808907] [PMID: 19164187]
[75]
Harper GD, Neill P, Vathenen AS, Cookson JB, Ebden P. A comparison of inhaled beclomethasone dipropionateand nedocromil sodium as additional therapy in asthma. Respir Med 1990; 84(6): 463-9.
[http://dx.doi.org/10.1016/S0954-6111(08)80110-2] [PMID: 2177216]
[76]
Boulet LP, Reddel HK, Bateman E, Pedersen S, FitzGerald JM, O’Byrne PM. The global initiative for asthma (GINA): 25 years later. Eur Respir J 2019; 54(2): 1900598.
[http://dx.doi.org/10.1183/13993003.00598-2019] [PMID: 31273040]
[77]
Agusti A, Fabbri L, Lahousse L, Singh D, Papi A. Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications. Allergy 2022; 77(4): 1105-13.
[http://dx.doi.org/10.1111/all.15076] [PMID: 34478578]
[78]
Reddel HK, Bateman ED, Schatz M, Krishnan JA, Cloutier MM. A practical guide to implementing SMART in asthma management. J Allergy Clin Immunol Pract 2022; 10(1): S31-8.
[http://dx.doi.org/10.1016/j.jaip.2021.10.011] [PMID: 34666208]
[79]
Garg R, Piplani M, Upadhayay A, Bhateja P. Correlation between demographic characteristics and degree of illness among asthmatic patients in the panchkula region. Eur Chem Bull 2023; 12((Special Issue 5)): 4868-74.
[80]
Garg R, Piplani M, Singh Y, Bhateja P, Rana R. An overview of integrated risk factors with prevention and prevalence of asthma at the global level. Curr Tradit Med 2023; 10: e250523217358.
[http://dx.doi.org/10.2174/2215083810666230525153908]
[81]
Gottwalt B, Tadi P. Methylxanthines. StatPearls 2023.
[82]
To Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide-3-kinase-δ with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182(7): 897-904.
[http://dx.doi.org/10.1164/rccm.200906-0937OC] [PMID: 20224070]
[83]
Cosío BG, Dacal D, Pérez de Llano L. Asthma-COPD overlap: Identification and optimal treatment. Ther Adv Respir Dis 2018; 12.
[http://dx.doi.org/10.1177/1753466618805662] [PMID: 30336736]
[84]
Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021: Executive summary and rationale for key changes. Am J Respir Crit Care Med 2022; 205(1): 17-35.
[http://dx.doi.org/10.1164/rccm.202109-2205PP] [PMID: 34658302]
[85]
Clinical Practice Guidelines. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda (MD): National Heart, Lung, and Blood Institute (US) 2003.
[86]
Möllmann H, Rohdewald P, Schmidt EW, Salomon V, Derendorf H. Pharmacokinetics of triamcinolone acetonide and its phosphate ester. Eur J Clin Pharmacol 1985; 29(1): 85-9.
[http://dx.doi.org/10.1007/BF00547374] [PMID: 4054209]
[87]
Moy ML, Israel E, Weiss ST, Juniper EF, Dubé L, Drazen JM. Clinical predictors of health-related quality of life depend on asthma severity. Am J Respir Crit Care Med 2001; 163(4): 924-9.
[http://dx.doi.org/10.1164/ajrccm.163.4.2008014] [PMID: 11282767]
[88]
Vollmer WM, Markson L, O’Connor E, et al. Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med 1999; 160(5): 1647-52.
[http://dx.doi.org/10.1164/ajrccm.160.5.9902098] [PMID: 10556135]
[89]
Waalkens HJ, Van Essen-Zandvliet EE, Hughes MD, et al. Cessation of long-term treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration. Am Rev Respir Dis 1993; 148(5): 1252-7.
[http://dx.doi.org/10.1164/ajrccm/148.5.1252] [PMID: 8239161]
[90]
Cheng ZR, Tan YH, Teoh OH, Lee JH. Keeping pace with adolescent asthma: A practical approach to optimizing care. Pulm Ther 2022; 8(1): 123-37.
[http://dx.doi.org/10.1007/s41030-021-00177-2] [PMID: 34743311]
[91]
Cloutier MM, Dixon AE, Krishnan JA, Lemanske RF Jr, Pace W, Schatz M. Managing asthma in adolescents and adults: 2020 asthma guideline update from the national asthma education and prevention program. JAMA 2020; 324(22): 2301-17.
[http://dx.doi.org/10.1001/jama.2020.21974] [PMID: 33270095]
[92]
Scarfone RJ, Teach SJ. Acute asthma exacerbations in children younger than 12 years: Emergency department management. Waltham, MA: UpToDate 2020.
[93]
Ish P, Malhotra N, Gupta N. GINA 2020: What’s new and why? J Asthma 2021; 58(10): 1273-7.
[http://dx.doi.org/10.1080/02770903.2020.1788076] [PMID: 32586146]
[94]
Desforges JF, Larsen GL. Asthma in children. N Engl J Med 1992; 326(23): 1540-5.
[http://dx.doi.org/10.1056/NEJM199206043262306] [PMID: 1579137]
[95]
Martinez FD. Managing childhood asthma: Challenge of preventing exacerbations. Pediatrics 2009; 123 (Suppl. 3): S146-50.
[http://dx.doi.org/10.1542/peds.2008-2233D] [PMID: 19221157]
[96]
Quek JS, Tang WE, Chen E, Smith HE. Understanding the journeys of patients with an asthma exacerbation requiring urgent therapy at a primary care clinic. BMC Pulm Med 2022; 22(1): 231.
[http://dx.doi.org/10.1186/s12890-022-02024-9] [PMID: 35710361]
[97]
Hay WW Jr, Deterding RR. Current diagnosis & treatment pediatrics. McGraw-Hill Education 2014.
[98]
Fala L. Nucala (mepolizumab): First IL-5 antagonist monoclonal antibody FDA approved for maintenance treatment of patients with severe asthma. Am Health Drug Benefits 2016; 9((Spec Feature)): 106.
[99]
Boulet LP, Becker A, Bérubé D, Beveridge R, Ernst P. Canadian asthma consensus report, 1999. CMAJ 1999; 161(11): S1-S61.
[PMID: 10906907]
[100]
Farooq J, Khaliq SA, Ghuman F, Shaikh J, Azhar I. Study on allopathic and alternative treatments of asthma and factors influencing treatment choices. Evid Based Complement Alternat Med 2022; 2022: 1-8.
[http://dx.doi.org/10.1155/2022/4699414] [PMID: 36072402]
[101]
Baiardini I, Braido F, Brandi S, et al. The impact of GINA suggested drugs for the treatment of asthma on health-related quality of life: A GA 2 LEN review. Allergy 2008; 63(8): 1015-30.
[http://dx.doi.org/10.1111/j.1398-9995.2008.01823.x] [PMID: 18691305]
[102]
Vernon MK, Wiklund I, Bell JA, Dale P, Chapman KR. What do we know about asthma triggers? A review of the literature. J Asthma 2012; 49(10): 991-8.
[http://dx.doi.org/10.3109/02770903.2012.738268] [PMID: 23574397]
[103]
Cloutier MM, Baptist AP, Blake KV, et al. 2020 focused updates to the asthma management guidelines: A report from the national asthma education and prevention program coordinating committee expert panel working group. J Allergy Clin Immunol 2020; 146(6): 1217-70.
[http://dx.doi.org/10.1016/j.jaci.2020.10.003] [PMID: 33280709]
[104]
Holimon TD, Chafin CC, Self TH. Nocturnal asthma uncontrolled by inhaled corticosteroids: Theophylline or long-acting β2 agonists? Drugs 2001; 61(3): 391-418.
[http://dx.doi.org/10.2165/00003495-200161030-00007] [PMID: 11293649]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy